Market Place
Sourcing Support
Novartis loses latest bid to block generic version of blockbuster heart drug
17 Oct 2024 //
REUTERS
USV launches heart failure medication at ?8 per 50mg tablet
15 Oct 2024 //
EXPRESSPHARMA
Novartis loses initial bid to block generic of best-selling heart drug
13 Aug 2024 //
REUTERS
Zydus Life hits 52-week high on USFDA nod for Sacubitril and Valsartan
11 Jul 2024 //
ECONOMIC TIMES
Zydus Pharms Generic Sacubitril :Valsartan Receives Approval in US
09 Jul 2024 //
FDA
Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin
09 Feb 2024 //
PRESS RELEASE
USDMF for Sacubitril Sodium has been submitted With An Innovative Devp Strategy
20 Mar 2023 //
PRESS RELEASE
Novartis heart drug price may fall by 60% on generic rollouts
19 Jan 2023 //
ECONOMIC TIMES
Dr Reddy`s cuts price of cardiovascular drug Cidmus
19 Jan 2023 //
ECONOMIC TIMES
HC reserves order on Natco`s plea over patent for Novartis drug
11 Jan 2023 //
ECONOMIC TIMES
Top Novartis cardiac drug to go off patent
03 Dec 2022 //
ECONOMICTIMES
Novartis files FDA appeal in bid to block Entresto generics
17 Sep 2022 //
FIERCEPHARMA
Delhi HC restrains generic firms from making, selling patent drug of Novartis
03 Nov 2021 //
ECONOMICTIMES
Novartis Entresto® indicated for treatment of hypertension in China
10 Jun 2021 //
PRESS RELEASE
Sacubitril/valsartan not superior to valsartan alone in advanced HFrEF: LIFE
17 May 2021 //
HEALIO
Novartis whiffs on Entresto study after heart attacks that doesn`t going down
17 May 2021 //
ENDPTS
Novartis` Entresto came up short in a post-heart attack phase 3
27 Apr 2021 //
FIERCEPHARMA
FDA reviewers argue for Novartis ahead of Entresto advisory panel confab
14 Dec 2020 //
FIERCEPHARMA
Cosentyx, Entresto drive topline growth for Novartis in Q4
30 Jan 2020 //
PMLIVE
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
18 Nov 2019 //
PR NEWSWIRE
Novartis` Entresto falls short at Ph 3 in heart failure with preserved ejection
25 Jul 2019 //
PHARMAFILE
Novartis exercises option for RNA-targeting drug candidate
25 Feb 2019 //
IN-PHARMATECHNOLOGIST
Novartis expects a parade to blockbusterland, with Entresto leading the way
30 Jan 2019 //
FIERCE PHARMA
Valsartan recall: 4 things patients should know
20 Jul 2018 //
CNN
Authorised products containing valsartan as active substance: Overview
16 Jul 2018 //
SWISSMEDIC
Real-world data finds patients feel better on Entresto, says Novartis
29 May 2018 //
PMLIVE
Novartis Boosts Cardiovascular Pipeline with $1bn Ionis Deal
10 Jan 2017 //
PMLIVE
NICE backs restricted use of heart drug Entresto
28 Apr 2016 //
PHARMA TIMES
ICER Releases Final Report on CardioMEMS HF System™ and Entresto™
01 Dec 2015 //
ICER-REVIEW
Novartis heart failure medicine Entresto™ substantially cuts 30day readmissions
10 Nov 2015 //
PR NEWS WIRE
Novartis` heart failure medicine Entresto recommended for EU approval
25 Sep 2015 //
MARKET WATCH
Swiss giant to make key heart failure drug here
21 Sep 2015 //
STRAITS TIMES
Novartis Says Swissmedic Approves Entresto In Heart Failure
17 Sep 2015 //
NASDAQ
Faster track to `megablockbuster`? Novartis` Entresto already soaring on social media
16 Sep 2015 //
FIERCE PHARMA MARKETTING
Is The Superiority Of Entresto Just An Illusion?
14 Sep 2015 //
FORBES
Treato Finds Demand Will be High for Heart Failure Drug Entresto
09 Sep 2015 //
PR NEWS WIRE
Novartis CEO: Payers not sold on performance pricing yet, but that`ll change
08 Sep 2015 //
FIERCE PHARMA
Novartis to start human tests with Google lens in 2016
07 Sep 2015 //
THE ECONOMIC TIMES
Lcz696 targets blood pressure and arterial stiffness
31 Aug 2015 //
SCIENCE DAILY
